The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation  by Osadnik, Tadeusz et al.
P.O. Box 2925 Riyadh – 11461KSA
Tel: +966 1 2520088 ext 40151
Fax: +966 1 2520718
Email: sha@sha.org.sa
URL: www.sha.org.sa
FU
LL LEN
G
TH
 A
RTIC
LE
Disclosure: Authors have nothing to disclose with regard to commercial
support.
Received 5 November 2014; revised 23 January 2015; accepted 9 February
2015.
Available online 17 February 2015
⇑ Corresponding author at: Silesian Center for Heart Diseases, Ul.
Marii Skłodowskiej Curie 9, 41-800 Zabrze, Poland. Tel.: +48 32 373 36 19;
fax: +48 32 273 26 79.
E-mail address: tadeusz.osadnik@sccs.pl (T. Osadnik).The platelet-to-lymphocyte ratio as a
predictor of all-cause mortality in patients
with coronary artery disease undergoing
elective percutaneous coronary intervention
and stent implantation1016–7315  2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under th
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
http://dx.doi.org/10.1016/j.jsha.2015.02.004 Production and hosting by ElsevierTadeusz Osadnik a,⇑, Jarosław Wasilewski a, Andrzej Lekston a, Joanna Strzelczyk b,
Anna Kurek a, Małgorzata Gonera a, Marcin Gawlita a, Rafał Reguła a, Kamil Bujak a,
Bo _zena Szyguła-Jurkiewicz a, Andrzej Wiczkowski b, Lech Polon´ski aa Medical University of Silesia, School of Medicine with the Division of Dentistry, IIIrd Chair and Department of Cardiology,
Silesian Centre for Heart Diseases, Zabrze
b Medical University of Silesia, School of Medicine with the Division of Dentistry, Department of Medical Biology, Zabrze
a,b Poland
Background: There is no data regarding the association between the platelet-to-lymphocyte ratio (PLR) and long-term
mortality in patients with stable coronary artery disease (SCAD). The aim of this study is to evaluate the utility of the
pre-procedural PLR for predicting long-term, all-cause mortality in patients with SCAD undergoing percutaneous
coronary intervention (PCI) and stent implantation.
Methods: We analyzed a total of 2959 consecutive patients with SCAD who underwent PCI (balloon angioplasty
followed by stent implantation or direct stenting) between July 2006 and December 2011 at our institution. The
patients were stratified into tertiles according to their admission PLR. The association between the PLR value
and the outcomes was assessed using Cox proportional regression analysis after adjusting for clinical angiographic
and laboratory data.
Results: During median follow-up of 1124 days, mortality was highest in patients with PLR within the 3rd tertile
as compared to the 2nd and the 1st tertile (11.0% vs 8.7% vs. 9.6%, respectively, p = 0.03). PLR remained associated
with mortality in multivariable analysis including clinical variables, ejection fraction and angiographic parameters
HR (per 10 units increase) = 1.02 [95%CI,1.01  1.04, p = 0.006]. After adjustment for the eGFR and hemoglobin
levels, PLR was however no longer significantly associated with mortality.
Conclusion: PLR has potential predictive value in patients with SCAD, which has not been reported previously,
but statistical significance disappears after adjusting for estimated glomerular filtration rate (eGFR) and hemoglobin
levels as a potential confounding variable.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
HF heart failure
PLR platelet/lymphocyte ratio
NSTEMI non-ST-elevation myocardial infarction
STEMI ST elevation myocardial infarction
MI myocardial infarction
PCI percutaneous coronary intervention
SCAD stable coronary artery disease
CABG coronary artery bypass grafting
COPD chronic obstructive pulmonary disease
BMI body mass index
EF ejection fraction
Hb hemoglobin
eGFR estimated glomerular filtration rate
CKD-EPI Chronic Kidney Disease Epidemiology Collabora-
tion
CCS Canadian Cardiovascular Society
NYHA New York Heart Association
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UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION AND STENT IMPLANTATIONIntroduction
Numerous studies have shown the associationbetween elevated platelet counts and car-
diovascular mortality [1–3]. It has been also shown
that the elevated level of neutrophils and relative
lymphocytopenia are negative prognostic indexes
of outcomes in patients with coronary artery
disease and heart failure (HF) [4–9].
Platelet-to-lymphocyte ratio (PLR) which can be
derived from the complete blood count is a novel
index reflecting a systemic inflammatory burden
that combines prognostic values of an individual’s
platelet and lymphocyte count [4,9]. In patients
with non-ST-elevation myocardial infarction
(NSTEMI) and ST elevation myocardial infarction
(STEMI), the PLR ratio is an independent
predictor of mortality [10,11].
Moreover, in patients with myocardial infarction
(MI) treated by primary PCI, PLR is an indepen-
dent risk factor for more advanced coronary artery
disease as reflected by higher Syntax scores and
no-reflow phenomenon [12]. Data regarding PLR
and its association with long-term prognosis in
stable coronary artery disease (SCAD) patients
are, however, lacking. We hypothesized that PLR
is a potential marker of prognostic importance in
patients with SCAD. The aim of our study was to
establish the impact of the baseline PLR ratio on
all-cause, long-term mortality in patients after
PCI and stent implantation.Methods
Data collection
For the purpose of this study, we examined a
computer database to identify patients with SCAD
referred to the Silesian Center for Heart Diseases
in Poland who underwent coronary angiography
and stent implantation between July 2006 and
December 2011. In this database, information on
coronary intervention, concomitant diseases,
demographic data and laboratory parameters
such as platelet and leukocyte counts are stored.
The complete blood counts, which included total
white blood cells, neutrophils, lymphocytes and
platelets, were obtained using an automated
blood counter Sysmex XS1000i and XE2100
(Sysmex Corporation, Kobe, Japan). Platelet-to-
lymphocyte ratio was calculated as the ratio of
the platelets to lymphocytes, obtained from the
blood samples that were taken at the fasting state.
Patients undergoing hybrid revascularization,
patients after orthotropic heart transplant,patients with known hematological diseases,
patients on dialysis, or with other diseases limit-
ing survival were excluded from the analysis.
One patient died during the in-hospital period
due to periprocedural complications. This patient
was also excluded from this analysis.
The study was approved by the Local Ethics
Committee at the District Chamber of Physicians.
Follow-up data
Information on survival was based on the
National Health Fund insurance status, which
can be electronically verified because the National
Health Fund insurance policy is obligatory for all
Polish citizens, and patients who were insured
were marked as alive. We made an attempt to con-
tact the relatives of uninsured patients and/or the
relevant local registry office to obtain the date of
death. Complete follow-up data (including even-
tual event and time of the event) were available
for 2947 (99.6%) patients.
Statistical analysis
The normality of continuous variable distribu-
tion was tested with a Shapiro-Wilk test and
deviation from the normal distribution was
inspected by analysis of the normal probability
plots (Quantile-Quantile plots). The continuous
variables are not normally distributed, and are
therefore presented as median and interquartile
ranges. The dichotomous variables are presented
as percentages. Patients were divided into sub-
groups according to PLR tertiles. Group I included
patients with PLR < 87 (n = 986); group II included
patients with PLR value of P87 and < 121
(n = 986); and group III included patients with
PLRP 121 (n = 987).
FU
LL LEN
G
TH
 A
RTIC
LE
146 OSADNIK ET AL
THE PLATELET-TO-LYMPHOCYTE RATIO AS A PREDICTOR
OF ALL-CAUSE MORTALITY IN PATIENTS WITH CORONARY
J Saudi Heart Assoc
2015;27:144–151To test for differences between the groups, the
Kruskal–Wallis test and chi-square test were used
for continuous variables, and dichotomous vari-
ables, respectively. The associations between
groups and mortality were analyzed using the
Kaplan-Meier method with log-rank testing. To
assess the impact of the PLR on prognosis, a uni-
variable and multivariable Cox regression analysis
was performed. Variables used in the univariable
Cox regression analysis included clinical, angio-
graphic, and laboratory parameters. Sex, history
of MI, previous PCI, previous coronary artery
bypass grafting (CABG), previous stroke,
hypercholesterolemia, hypertension, atrial fibril-
lation, diabetes, chronic obstructive pulmonary
disease (COPD), family history of premature
(<55 years of age) MI and sinus rhythm at admis-
sion were analyzed as dichotomous variables.
Age, body mass index (BMI), ejection fraction
(EF), hemoglobin (Hb), creatinine, sodium, and
total cholesterol were analyzed as a continuous
variable. Estimated glomerular filtration rate
(eGFR) was calculated by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI)
formula [13] and was analyzed as a continuous
variable, per 10 ml/min/1.73m2 increment. PLR
was analyzed as a continuous variable per 10 units
increase. Admission platelets and lymphocyte
counts were excluded from the analysis as they
were used to calculate PLR. The Canadian Cardio-
vascular Society (CCS) class was categorized as
CCS class I and II vs. CCS class III and IV. Heart
failure was categorized as ‘‘no heart failure’’ and
‘‘heart failure with symptoms in New York Heart
Association Class (NYHA) I/II’’ and ‘‘heart failure
with symptoms in NYHA class III/IV’’. Smoking
was categorized as ‘‘current smoker’’, ‘‘former
smoker’’ and ‘‘never smoked’’. Type of stent
implanted was categorized as ‘‘bare metal stent’’,
‘‘drug eluting stent’’ or ‘‘both’’. The number of
stents implanted and number of PCI vessels were
analyzed as ordinal categories. To minimize the
impact of missing data on the Cox regression ana-
lysis, the multiple imputation method was used to
impute missing data for the variables that were to
be included in the Cox regression procedures.
There were missing data regarding information
on the BMI – 253 (8.6%), EF – 314 (10.6%), family
history of premature coronary heart disease – 8
(0.3%). Hemodynamic data was available for all
patients and was taken from angiography reports.
Data on mortality was missing for 14 (0.5%)
patients. Additionally for three (0.1%) patients,
we were not able to establish the exact time of
death.To minimize the impact of the missing data on
the multivariable Cox regression analysis, we
used the missForest algorithm for mixed type data
imputation [14]. All above-mentioned variables
including the outcome variable were entered into
the multiple imputation algorithm. We used the
missForest R–package [15].
We performed Cox regression analysis on the
imputed dataset. Variables that reached p-value
lower than 0.2 in the univariable analysis were
included in the multivariable model. We used
backwards selection procedures to obtain vari-
ables significantly associated with long-term
mortality in multivariable analysis. We created
four models including PLR and clinical variables
(model 1), clinical variables and ejection fractions
(model 2), clinical variables, ejection fractions
and angiographic parameters (number of stents
implanted, number of PCI vessels, presence of
multi-vessel coronary artery disease) (model 3),
and additionally also hemoglobin and eGFR
(model 4). We calculated Harrell’s concordance
index (Harrell’s C-statistics) which describes
discriminative ability of risk models obtained with
the use of Cox-regression analysis. Harrell’s
C-statistics range from 0.5 (no predictive ability)
to 1.0 (perfect discrimination). The analyses were
performed using Number Crunching Statistical
Systems 8.0 (NCSS, Kaysville, UT, USA) and R
software [16]. Figure was prepared using Graph
Pad Prism Software (La Jolla, USA).
The creation of the database of patients with
SCAD used in this study was supported by the
National Science Center – Dec-2011/01/D/NZ5/
04387.Results
The study sample consisted of a cohort of
2959 patients with SCAD (2094 males), with a
median age of 64.00 (IQR: 57  71 years). The
baseline demographic characteristics of patients
stratified by the PLR tertiles are demonstrated
in Table 1. The patients in the 3rd PLR tertile
were significantly older, more often female and
hypertensive whilst less often smokers and obe-
se, as compared to patients in the 1st and 2nd
PLR tertile. According to the admission labora-
tory work-up, patients in the 3rd PLR tertile
had significantly lower red and white blood cell
counts, sodium concentration, Hb levels and
eGFR (Table 2). There were no differences
between patients stratified by the PLR tertiles
in the prescribed treatment at hospital discharge
(Table 3).
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Table 1. Baseline clinical characteristics of analyzed cohort according to PLR values.
Variable 1st tertile, (n = 986) 2nd tertile, (n = 986) 3rd tertile, (n = 987) P value
Age (yrs) 62.0 [56.0  69.0] 65.0 [57.0  71.0] 65.0 [58.0  72.0] <0.01
Men (%) 746 (75.7%) 693 (70.3%) 655 (66.4%) <0.01
Heart failure NYHA class I/II 107 (10.9%) 93 (9.4%) 101 (10.2%) 0.70
NYHA class III/IV 33 (3.3%) 42 (4.3%) 40 (4.1%)
Atrial fibrillation 104 (10.5%) 106 (10.8%) 110 (11.1%) 0.91
Hypertension 698 (70.8%) 686 (69.6%) 740 (75.0%) 0.02
Previous MI 578 (58.6%) 562 (57.0%) 589 (59.7%) 0.48
Previous CABG 136 (13.8%) 134 (13.6%) 108 (10.9%) 0.11
Previous PCI 460 (46.9%) 485 (49.4%) 504 (51.1%) 0.17
Previous SCD 28 (2.8%) 31 (3.1%) 26 (2.6%) 0.79
PVD 66 (6.7%) 48 (4.9%) 54 (5.5%) 0.20
Prev. Stroke/TIA 39 (4.0%) 47 (4.8%) 46 (4.7%) 0.64
Diabetes mellitus 366 (37.1%) 344 (34.9%) 365 (37.0%) 0.51
Lipid abnormalities 576 (58.4%) 564 (57.2%) 544 (55.1%) 0.33
COPD 68 (6.9%) 71(7.2%) 76 (7.7%) 0.79
Obesity 328 (36.5%) 300 (33.3%) 264 29.1 (%) <0.01
Current smoker 144 (14.6%) 97 (9.9%) 89 (9.0%) <0.01
Previous smoker 376 (38.2%) 356 (36.2%) 343 (34.8%)
FH of premature 87 (8.8%) 96 (9.8%) 87 (8.8%) 0.71
CCS class I/II 826 (83.8%) 821 (83.3%) 832 (84.3%) 0.82
III/IV 160 (16.2%) 165 (16.7%) 155 (15.7%)
In sinus rhythm at admission 64 (6.5%) 54 (5.5%) 59 (6.0%) 0.63
Ejection fraction (%) 48.0 [40.0  53.5] 48.0 [40.0  55.0] 50.0 [42.0  55.0] 0.08
BMS 582 (59.0%) 529 (53.7%) 535 (54.2%) 0.11
DES 368 (37.3%) 417 (42.3%) 417 (42.2%)
BMS + DES 36 (3.7%) 40 (4.1%) 35 (3.5%)
MVD 194 (19.7%) 189 (19.2%) 196 (19.9%) 0.92
No. of PCI vessels 1 786 (79.7%) 781 (79.2%) 791 (80.1%) 0.60
No. of PCI vessels 2 166 (16.8%) 176 (17.8%) 168 (17.0%)
No. of PCI 3 34 (3.0%) 29 (2.7%) 28 (2.3%)
No. of stents 1 715 (72.5%) 678 (68.8%) 679 (68.8%) 0.62
No. of stents 2 212 (21.5%) 246 (24.9%) 241 (24.4%)
No. of stents 3 48 (4.9%) 54 (5.5%) 58 (5.9%)
P4 10 (0.7%) 8 (0.7%) 9 (0.7%)
BMI 28.4 [26.031.3] 28.0 [25.330.8] 27.7 [25.230.5] <0.01
Abbreviations: BMI - body mass index, BMS – bare metal stent, CABG – coronary artery bypass grafting, CCS – Canadian Cardiovascular Society,
COPD - chronic obstructive pulmonary disease, DES – drug-eluting stent, FH – family history, MI – myocardial infarction, MVD – multivessel disease,
NYHA – New York Heart Association, PCI – percutaneous coronary intervention, PVD – peripheral vascular disease, SCD - sudden cardiac death,
TIA - transient ischemic attack.
Table 2. Laboratory findings at hospital admission in the analyzed cohort according to PLR values.
Variable 1st tertile, N = 986 2nd tertile, N = 986 3rd tertile, N = 987 P value
RBC (106/mm3) 4.6 [4.3  4.9] 4.5 [4.2  4.8] 4.5 [4.1  4.8] <0.01
Hb (mmol/l) 8.8 [8.2  9.3] 8.7 [8.1  9.2] 8.4 [7.8  9.0] <0.01
HCT (%) 42.0 [39.0  45.0] 41.0 [39.0  44.0] 37.0 [40.0  44.0] <0.01
WBC (103/mm3) 7.6 [6.4  8.9] 6.8 [5.9  8.1] 6.8 [5.7  8.1] <0.01
Neutrophils (103/mm3) 4.0 [3.2  5.0] 4.0 [3.2  5.0] 4.3 [3.5  5.5] <0.01
Lymphocyte (103/mm3) 2.6 [2.2  3.1] 2.0 [1.7  2.3] 1.5 [1.2  1.8] <0.01
PLT (103/mm3) 176 [148  206] 204 [175  236] 239 [203  283] <0.01
eGFR (ml/min/1.73 m2) 85.5[71.0  96.1] 85.4 [69.4  95.3] 84.1 [67.6  94.9] <0.01
Sodium (mmol/l) 138.9 [137.1  140.4] 138.6 [137.0  140.2] 138.2 [136.6  139.9] <0.01
Cholesterol (mmol/l) 4.4 [3.7  5.2] 4.4 [3.7  5.2] 4.4 [3.6  5.2] 0.71
PLR 70.0 [59.7  78.1] 102.3 [94.3  111.7] 149.4 [132.5  183.2] <0.01
Abbreviations: eGFR – estimated glomerular filtration rate, Hb – hemoglobin, HCT – hematocrit, PLR – platelet/lymphocyte ratio, PLT – platelets,
RBC – red blood cells, WBC – white blood cells.
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Figure 1. Kaplan–Meier survival plots for risk of death from all-cause, categorized according to the PLR ratio tertiles during follow-up.
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Table 3. Treatment at hospital discharge according to PLR values.
Variable 1st tertile, N = 986 2nd tertile, N = 986 3rd tertile, N = 987 P value
Aspirin 975 (98.9%) 977 (99.1%) 975 (98.8%) 0.80
Thienopyridines 975 (98.9%) 978 (99.2%) 984 (99.7%) 0.11
ACE-I/ARB 928 (94.1%) 920 (93.3%) 923 (93.5%) 0.65
Beta-blockers 946 (95.9%) 942 (95.5%) 945 (95.7%) 0.91
Diuretics 349 (35.4%) 335 (34.0%) 368 (37.3%) 0.31
Statin 955 (96.9%) 953 (96.7%) 948 (96.0%) 0.59
Abbreviations: ACE-I – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blockers.
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Follow-up data (including eventual event and
time of the event) were available for 2947 (99.6%)
patients. The median follow-up was 1124 days
(interquartile range 586  1594 days). During the
observation period, 287 deaths were reported. Mor-
tality was highest in the 3rd tertile 108/983 (11.0%)
as compared to the 1st 94/981 (9.6%) and 2nd tertile
85/981 (8.7%) (p = 0.03, log rank). Kaplan–Maier
curves for survival are depicted in Fig. 1.
Platelet-to-lymphocyte ratio was significantly
associated with mortality in the univariable analy-
sis (Fig. 2). It remained significantly associated
with long-term mortality after consecutive adjust-
ments for clinical variables (model 1), EF (model 2)
and angiographic data (model 3). However, after
adjustment for hemoglobin and eGFR, PLR
was no longer significantly associated with the
outcomes (model 4, Fig. 2).Discussion
Platelet-to-lymphocyte ratio is a repeatable and
easily obtainable blood index of the systemicinflammatory burden that combines both a prog-
nostic value of the individual platelet and lympho-
cyte counts [4,9]. It has been found to be elevated
in patients suffering from various oncologic
disorders [17]. Platelet-to-lymphocyte ratio is a
predictor of mortality in a cancer population
[18–21] and a useful biomarker for predicting
response to first-line chemotherapy [22].
Some studies have identified high platelet
counts and worse outcomes after PCI [2,3], and
the negative predictive role of lymphocyte counts
in patients with coronary artery disease [7],
unstable angina [6], and heart failure [4,5,8,9,23].
To our knowledge, no research has evaluated the
significance of the PLR value in predicting
long-term mortality in SCAD patients treated by
elective PCI.
Gary et al. [24] reported that in patients with
peripheral arterial occlusive disease, PLR ratio
value of more than 150 can be used to discriminate
patients at high risk for critical limb ischemia from
those with a low risk. Additionally, it has been
demonstrated that elevated platelet counts were
independently associated with platelet resistance
to aspirin [25], and increased PLR with a risk of
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Figure 2. Risk associated with an increase in PLR in the setting of unadjusted analysis and after inclusion of clinical variables (model 1, Harrell’s
C-statistics 0.742 [0.71  0.77]), ejection fraction (model 2, Harrell’s C-statistics 0.745 [0.71  0.78]), angiographic data (model 3, Harrell’s
C-statistics 0.749 [0.72  0.78]) and laboratory parameters (model 4, Harrell’s C-statistics – 0.762 [0.73  0.79]).
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patients within the 3rd PLR tertile value were old-
er, with a higher prevalence of female gender, a
lower frequency of smoking, and lower body mass
index compared to those within lower PLR tertiles.
In addition, patients in the 3rd PLR tertile were
more frequently hypertensive and had a higher
heart rate at admission. The results of our study
are in line with the findings of Gary at al, suggest-
ing age influences on the PLR value [24].
Platelet-to-lymphocyte ratio was also found to
be a marker of long-term mortality in patients
with MI [10,12], and it was associated with more
advanced coronary artery disease, in-hospital
adverse events, and stent thrombosis in patients
with STEMI treated with primary PCI [27,28].
In our study, we are able to demonstrate that a
high PLR is a predictor of poor outcomes in
patients after PCI and stent implantation after
adjusting for clinical features, EF, and angiograph-
ic parameters (Fig. 2), but not after adjustment for
hemoglobin and eGFR, which are well known pre-
dictors of long-term prognosis in that group of
patients [29,30].
The mechanisms of the poor long-term out-
comes of patients with elevated PLR discussed in
the literature are multifactorial and not fully
understood. It has long been recognized that low
grade inflammation plays a key role in all aspects
of atherosclerosis, including plaque formation,
plaque rupture, and thrombosis. Prior studiesreveal an association between major adverse car-
diovascular outcomes and both higher platelet
and low lymphocyte counts in patients with
NSTEMI [10].
Abnormally low lymphocyte count was found to
be a predictor of an overall mortality and MI in
patients presenting to the emergency room with
chest pain [31], and was associated with adverse
clinical outcomes in patients with SCAD and
NSTEMI [7,10]. On the contrary as platelets
release over 300 proteins and molecules, including
chemokines, and coagulation factors [32], higher
platelet counts may reflect underlying inflamma-
tion and thrombocyte activation. In connection
with its ability to ‘cross-talk’ with endothelial cells
and leukocytes, platelets release substances that
increase adhesion and transmigration of mono-
cytes, therefore leading to a more aggressive
course of atherosclerosis [33,34]. Indeed, platelet-
neutrophil binding occurs after PCI [35]. However,
inflammatory mediators and stress-induced
steroid exposure can decrease the number of
lymphocytes and hence modify the PLR [36]. At
the end-stage renal disease, PLR is also positively
correlated with the neutrophil-to-lymphocyte
ratio, interleukin-6 and tumor necrosis factor-a,
which are known mediators of inflammation [37].
Apart from its pro-inflammatory rating, PLR is
also positively correlated with fibrinogen which
leads to an increase in blood viscosity and there-
fore impairment of the tissue oxygen supply
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Ayça et al, which proves that PLR is a predictor
of no-reflow phenomenon in STEMI patients,
and with our previous publication showing that
baseline fibrinogen concentration in STEMI
patients is an independent risk factor of the lack
of myocardial reperfusion [27,40].
It has been also reported that an elevated plate-
let count is an independent predictor of aspirin
resistance which may also affect outcomes in
patients treated with stent implantation [25].
In summary, PLR is a surrogate marker of sys-
temic inflammation and, as such, may provide
an explanation for increased cardiovascular risk.
Moreover, it could be assumed that high platelet
concentrations and low lymphocyte counts may
contribute to the progression of atherosclerosis,
may accelerate restenosis and plaque instability,
and hence be associated with worse prognosis in
SCAD and patients with MI [10,11].Strengths and limitations
This study has several limitations. It is a single-
center retrospective study, and we used a single
blood sample to calculate PLR. Nonetheless, the
potential disadvantages of the retrospective analy-
sis are diminished by the fact that patients’ data
were inputted into an electronic database from
report forms filled out by the attending physician
upon the patient’s admission to our center.
Strengths of this study include large cohort,
detailed data on clinical, hemodynamic and
laboratory parameters, and a long follow-up
period with very few patients lost to follow-up.Conclusion
Mortality in patients with SCAD undergoing
elective stent implantation is higher in patients
with the highest PLR values; and PLR has predic-
tive value for all-cause long-term mortality in
patients undergoing PCI and stent implantation,
even after adjusting for the possible confounders,
including clinical features, EF and angiographic
data but not laboratory parameters. Future studies
are warranted to clarify the prognostic value of
PLR on cardiovascular event rates and all-cause
mortality in SCAD patients.Acknowledgements
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